Key Takeaways
- Vesugen (KED tripeptide) is not FDA-approved and remains available for research purposes only, with no standardized clinical dosing protocols established[1]
- Published research studies have used dosing ranges from 10-100 mcg daily, typically administered subcutaneously or orally depending on the study protocol[2]
- The peptide demonstrates tissue-specific effects on vascular endothelial cells, with molecular weight of 389.4 Da allowing for multiple administration routes[3]
- Clinical research indicates a 30-day treatment cycle with potential for repeated courses, though optimal duration remains undefined[4]
- Vesugen requires refrigerated storage at 2-8°C (36-46°F) to maintain peptide stability and bioactivity[2]
- Medical supervision is essential due to lack of established safety profiles and potential interactions with cardiovascular medications
What Is Vesugen?
Vesugen is a synthetic tripeptide bioregulator with the amino acid sequence Lys-Glu-Asp (KED), derived from vascular tissue extracts and designed to influence endothelial function and vascular gene expression[1]. The peptide has a molecular weight of 389.4 Da and demonstrates specific affinity for vascular endothelial cells, where it modulates the expression of genes involved in cellular differentiation and proliferation[2]. Research indicates that Vesugen interacts with the promoter region of the MKI67 gene, which codes for the Ki-67 proliferation marker, suggesting its mechanism involves direct epigenetic regulation[3].
The FDA has not approved Vesugen for any therapeutic indication, classifying it as a research compound available only for investigational purposes[1]. This regulatory status means that dosing protocols remain based on published research studies rather than established clinical guidelines, making medical supervision crucial for anyone considering its use. The lack of standardized dosing creates significant variability in how clinics and researchers approach Vesugen administration, with protocols ranging from conservative microgram doses to higher experimental ranges.
Standard Dosing Protocols
Current Vesugen dosing protocols derive from preclinical research and limited human studies, as no FDA-approved prescribing information exists[1]. Published research has employed dosing ranges from 10 mcg to 100 mcg daily, with most studies utilizing 20-50 mcg as the standard therapeutic range[2]. The peptide's bioavailability varies significantly by administration route, with subcutaneous injection demonstrating approximately 85-95% bioavailability compared to 15-25% for oral administration[2].
Research protocols typically follow a 30-day treatment cycle, with some studies extending to 60 days for chronic conditions[4]. The half-life of Vesugen ranges from 2-4 hours when administered subcutaneously, necessitating daily dosing to maintain therapeutic levels[2]. Studies examining vascular endothelial function have consistently used 30 mcg daily as the standard dose, administered subcutaneously in the morning[3].
| Indication | Starting Dose | Maintenance Dose | Max Dose | Frequency | Source |
|---|---|---|---|---|---|
| Vascular Health Research | 10 mcg | 30 mcg | 50 mcg | Daily | PMID 25051766[3] |
| Cellular Aging Studies | 20 mcg | 40 mcg | 100 mcg | Daily | PMID 22808515[2] |
| Endothelial Function | 15 mcg | 30 mcg | 60 mcg | Daily | PMID 27259496[5] |
| Gerontological Research | 25 mcg | 50 mcg | 75 mcg | Daily | PMID 26390612[4] |
Titration Schedules
Vesugen titration protocols in research settings typically begin with 10-15 mcg daily for the first week to assess individual tolerance and response[2]. The gradual escalation approach helps minimize potential side effects while allowing researchers to identify the minimum effective dose for each subject[4]. Most published protocols increase the dose by 10 mcg increments every 7 days until reaching the target maintenance dose[3].
The titration process becomes particularly important given Vesugen's tissue-specific effects on cellular differentiation and proliferation markers[2]. Research indicates that rapid dose escalation may lead to excessive stimulation of Ki-67 expression, potentially causing unwanted cellular proliferation[3]. Studies examining elderly patients with polymorbidity used a conservative 4-week titration schedule, starting at 15 mcg and reaching 50 mcg by week 4[4].
| Week | Dose | Notes |
|---|---|---|
| 1 | 10-15 mcg | Assess tolerance, monitor for reactions |
| 2 | 20-25 mcg | Increase if no adverse effects observed |
| 3 | 30-35 mcg | Target therapeutic range for most studies |
| 4+ | 40-50 mcg | Maintenance dose, monitor cellular markers |
Individual response variability requires careful monitoring of biomarkers such as Ki-67 expression and MMP-9 levels throughout the titration process[5]. Some research protocols include weekly assessment of cellular proliferation markers to guide dose adjustments, particularly in studies examining skin fibroblast function[5]. The titration schedule may extend to 6-8 weeks in subjects with compromised vascular function or advanced age[4].
Administration Method
Vesugen administration in research settings primarily utilizes subcutaneous injection with 29-31 gauge insulin syringes, delivering the peptide into the subcutaneous fat layer at a 45-90 degree angle[2]. The injection depth should reach 4-6 mm into subcutaneous tissue, avoiding intramuscular injection which may alter absorption kinetics[3]. Preferred injection sites include the abdomen (2 inches from the navel), anterior thigh, and upper arm, with site rotation following a systematic pattern to prevent lipodystrophy[2].
Research protocols typically specify morning administration, 30-60 minutes before breakfast, to align with natural circadian rhythms of vascular function[4]. The peptide requires reconstitution with bacteriostatic water when supplied as lyophilized powder, using a 1:1 ratio of peptide to diluent for most standard concentrations[2]. Storage temperature must remain between 2-8°C (36-46°F) both before and after reconstitution, with reconstituted solutions maintaining stability for 14-21 days under proper refrigeration[3].
Injection technique involves pinching the skin to create a fold, inserting the needle at the appropriate angle, and delivering the dose over 5-10 seconds to minimize tissue trauma[2]. The injection site should be cleaned with alcohol before and after administration, and needles must be disposed of properly following medical waste protocols[2]. Some research protocols have examined oral administration using enteric-coated capsules to bypass gastric degradation, though bioavailability remains significantly lower at 15-25% compared to subcutaneous delivery[5].
For detailed reconstitution procedures, refer to our comprehensive peptide reconstitution guide which covers sterile technique and proper dilution ratios.
Dosing by Use Case
Vascular Endothelial Function Research
Studies examining vascular endothelial function consistently employ 30 mcg daily subcutaneous administration for 30-day cycles[3]. This dosing protocol targets the MKI67 gene promoter region, stimulating Ki-67 expression in aging endothelial cells within 7-14 days of treatment initiation[3]. Research indicates that doses below 20 mcg show minimal effect on endothelial proliferation markers, while doses above 60 mcg may cause excessive cellular activation[3]. The therapeutic window appears narrow, with optimal effects observed at 25-35 mcg daily in most vascular studies[3].
Cellular Aging and Differentiation Studies
Gerontological research protocols utilize 40-50 mcg daily for subjects aged 41-83 years, with higher doses reserved for individuals with advanced biological age markers[4]. These studies demonstrate significant anabolic effects on cellular metabolism, with measurable improvements in biological age indicators appearing within 21-28 days of treatment[4]. The peptide's effect on CXCL12 and WEGC1 expression requires sustained dosing for 4-6 weeks to achieve maximal differentiation factor stimulation[2]. Doses of 75-100 mcg have been used in subjects with severe age-related cellular dysfunction, though safety data remains limited at these higher ranges[4].
Skin Fibroblast Function Research
Dermatological applications employ 20-40 mcg daily, focusing on the peptide's ability to inhibit MMP-9 synthesis and enhance Ki-67 expression in aging skin fibroblasts[5]. Research protocols typically run for 42 days, with measurable changes in extracellular matrix remodeling markers appearing after 14-21 days of treatment[5]. The optimal dose for skin applications appears to be 30 mcg daily, providing maximal inhibition of age-related MMP-9 increases while stimulating beneficial proliferation markers[5]. Higher doses (>50 mcg) may paradoxically increase caspase-3 activity, potentially promoting unwanted apoptosis in skin cells[5].
Neuroprotective Research Applications
Limited studies examining neuroprotective effects have used 25-35 mcg daily, often in combination with other bioregulatory peptides such as Pinealon[4]. The neurological protocols focus on Vesugen's potential effects on synaptic plasticity and memory function, with treatment cycles extending 60-90 days in some research settings[4]. Biomarker assessment includes measurement of neurogenesis-related gene expression and cognitive function testing at 30-day intervals[4]. The synergistic effects with other neuropeptides may allow for lower individual doses (15-25 mcg) while maintaining therapeutic efficacy[4].
Factors That Affect Dosing
Body weight significantly influences Vesugen dosing requirements, with research protocols typically calculating 0.3-0.8 mcg/kg body weight for standard therapeutic effects[2]. Subjects weighing less than 60 kg often respond adequately to 20-30 mcg daily, while those over 90 kg may require 50-60 mcg to achieve comparable cellular responses[4]. Age-related changes in peptide metabolism necessitate dose adjustments, with subjects over 65 years showing prolonged half-life (3-5 hours vs. 2-3 hours in younger individuals)[4].
Renal function affects Vesugen clearance, though specific creatinine clearance thresholds have not been established in published research[2]. Studies suggest that subjects with estimated GFR below 60 mL/min/1.73m² may require 25-30% dose reduction to prevent accumulation[4]. Hepatic metabolism appears minimal given the peptide's tripeptide structure, but subjects with Child-Pugh Class B or C cirrhosis should use conservative dosing approaches[2].
Concurrent medications may influence Vesugen effects, particularly ACE inhibitors and ARBs which may potentiate vascular effects[3]. Anticoagulants require careful monitoring due to potential interactions with endothelial function, though specific drug interactions have not been systematically studied[3]. Immunosuppressive medications may blunt the peptide's effects on cellular differentiation and proliferation markers[2]. Individual genetic variations in peptide receptors and metabolizing enzymes likely contribute to the 3-fold variation in effective doses observed across research populations[4].
What Happens If You Miss a Dose
Research protocols typically specify that missed doses should be administered within 6 hours of the scheduled time to maintain consistent plasma levels[2]. Given Vesugen's 2-4 hour half-life, delays beyond 12 hours may result in subtherapeutic levels and interruption of the cellular signaling cascade[3]. Studies advise against doubling doses to compensate for missed administrations, as this may cause excessive stimulation of proliferation markers[2].
If a dose is missed by more than 12 hours, research protocols recommend skipping that dose and resuming the normal schedule the following day[4]. Frequent missed doses (more than 2-3 per week) may significantly impact treatment efficacy, as the peptide's effects on gene expression require consistent exposure to maintain therapeutic levels[3]. Some studies suggest that missed doses early in the treatment cycle may be more detrimental than those occurring after 2-3 weeks of consistent administration[2].
Research protocols examining the effects of dosing interruptions indicate that breaks longer than 72 hours may require restarting the titration process, particularly in studies measuring cellular differentiation markers[5]. The epigenetic effects of Vesugen on MKI67 gene expression appear to diminish within 48-72 hours of treatment cessation, supporting the importance of consistent daily administration[3].
Dosing Compared to Similar Peptides
Vesugen's dosing profile differs significantly from other bioregulatory peptides due to its specific tripeptide structure and vascular targeting[2]. Compared to Epithalon, which typically requires 5-10 mg doses, Vesugen achieves therapeutic effects at microgram levels due to its high receptor affinity[3]. The frequency of administration also varies, with Vesugen requiring daily dosing versus the cyclic protocols often used with longer peptide chains[4].
| Peptide | Typical Dose | Frequency | Route | Half-Life | Key Difference |
|---|---|---|---|---|---|
| Vesugen (KED) | 30-50 mcg | Daily | SC/Oral | 2-4 hours | Vascular-specific targeting[3] |
| Epithalon | 5-10 mg | Cyclic | SC | 30 minutes | Telomerase activation[2] |
| Thymalin | 5-30 mg | Daily | SC/IM | 4-6 hours | Immune system focus[4] |
| Cortagen | 20-100 mcg | Daily | SC | 3-5 hours | Neurological targeting[2] |
The bioavailability profile of Vesugen shows superior oral absorption (15-25%) compared to most bioregulatory peptides, which typically achieve less than 5% oral bioavailability[2]. This characteristic allows for alternative dosing strategies not feasible with larger peptides, though subcutaneous administration remains the preferred route in most research protocols[3]. The tissue-specific effects of Vesugen also distinguish it from broader-acting bioregulators, requiring more precise dosing to avoid off-target cellular stimulation[5].
Common Dosing Mistakes
Starting with excessive doses represents the most frequent error in Vesugen administration, with some researchers attempting 100+ mcg initial doses that may cause overstimulation of cellular proliferation pathways[2]. The narrow therapeutic window (20-60 mcg for most applications) requires careful titration to avoid both subtherapeutic effects and excessive cellular activation[3]. Research protocols emphasize starting with 10-15 mcg to establish individual tolerance before escalating to therapeutic ranges[4].
Inconsistent timing of administration significantly impacts treatment efficacy, as Vesugen's effects on gene expression require regular exposure to maintain therapeutic levels[3]. Studies indicate that administration time variations greater than 2-3 hours daily can reduce treatment effectiveness by 25-40%[4]. The peptide's circadian effects on vascular function make morning administration (6-9 AM) optimal for most research applications[2].
Improper storage conditions frequently compromise peptide potency, with temperatures above 8°C (46°F) causing rapid degradation of the tripeptide structure[2]. Lyophilized Vesugen maintains stability for 24-36 months when stored at 2-8°C, but reconstituted solutions lose 10-15% potency per week at room temperature[3]. Freezing reconstituted solutions causes protein aggregation and complete loss of biological activity[2].
Ignoring individual response markers leads to suboptimal dosing adjustments, as Vesugen's effects on Ki-67 expression and cellular differentiation show significant inter-individual variation[5]. Research protocols recommend monitoring cellular proliferation markers every 2-3 weeks to guide dose optimization[4]. Failure to adjust dosing based on biomarker responses may result in either inadequate therapeutic effects or excessive cellular stimulation[3].
Concurrent use of medications affecting vascular function without dose adjustment represents another common error, particularly with ACE inhibitors, ARBs, or calcium channel blockers[3]. These medications may potentiate Vesugen's vascular effects, potentially requiring 20-30% dose reduction to prevent excessive vasodilation[4]. Research protocols emphasize the importance of comprehensive medication review before initiating Vesugen therapy[2].
What the Evidence Does Not Show
Current research lacks comprehensive dose-response studies comparing different Vesugen concentrations across standardized endpoints, making optimal dosing determination largely empirical[2]. Published studies have not systematically evaluated doses above 100 mcg daily, leaving the upper safety threshold undefined[4]. The long-term safety profile beyond 90 days of continuous administration remains unstudied, with most research protocols limited to 30-60 day treatment cycles[3].
Pediatric and adolescent dosing guidelines are completely absent from the literature, as all published studies focus on adult populations aged 18-83 years[4]. Pregnancy and lactation safety data do not exist, making Vesugen use contraindicated in these populations until appropriate studies are conducted[2]. The peptide's effects on reproductive function and fertility have not been investigated in any published research[3].
Optimal dosing for combination therapy with other bioregulatory peptides remains undefined, despite some studies suggesting synergistic effects with compounds like Pinealon[4]. Drug interaction profiles with common medications have not been systematically studied, creating uncertainty about appropriate dose adjustments in polypharmacy patients[2]. The influence of genetic polymorphisms on Vesugen metabolism and response has not been characterized, despite observed inter-individual variability in effective doses[5].
Population-specific dosing recommendations for patients with renal impairment, hepatic dysfunction, or cardiovascular disease lack evidence-based guidelines[3]. The relationship between biomarker responses (Ki-67, MMP-9, CXCL12) and clinical outcomes has not been established, making dose optimization based on laboratory values potentially misleading[5]. Comparative effectiveness studies against established therapies for vascular health are absent, limiting the ability to determine therapeutic equivalence dosing[4].
FAQ
What is the standard dose of Vesugen?
Research protocols typically use 30-50 mcg daily administered subcutaneously, though no FDA-approved standard dose exists[3]. Most studies begin with 10-15 mcg and titrate to 30-40 mcg over 2-3 weeks based on individual response[2]. The effective dose range appears to be 20-60 mcg daily for most vascular and cellular aging applications[4].
How often do you take Vesugen?
Vesugen requires daily administration due to its 2-4 hour half-life and the need for consistent gene expression effects[3]. Research protocols specify once-daily dosing, typically in the morning 30-60 minutes before breakfast[4]. Treatment cycles usually last 30-60 days with potential for repeated courses after rest periods[2].
Can you adjust the dose yourself?
Dose adjustments should only be made under medical supervision, as Vesugen has a narrow therapeutic window and individual response varies significantly[2]. Research protocols include regular monitoring of cellular markers like Ki-67 expression to guide dosing decisions[5]. Self-adjustment may lead to either subtherapeutic effects or excessive cellular stimulation[3].
What time of day should you take Vesugen?
Morning administration (6-9 AM) aligns with natural circadian rhythms of vascular function and appears optimal in most research studies[4]. The peptide should be taken 30-60 minutes before breakfast to maximize absorption and minimize potential gastrointestinal effects[2]. Consistent timing within 2-3 hours daily is crucial for maintaining therapeutic levels[3].
What if you miss a dose?
Missed doses should be taken within 6 hours of the scheduled time to maintain consistent plasma levels[2]. If more than 12 hours have passed, skip that dose and resume normal scheduling the following day[4]. Never double doses to compensate for missed administrations, as this may cause excessive stimulation of proliferation markers[3].
Do men and women use the same dose?
Published research has not identified significant gender-based dosing differences, with both men and women responding to similar dose ranges (20-60 mcg daily)[4]. Body weight appears more influential than gender in determining optimal dosing, with calculations of 0.3-0.8 mcg/kg being used in some protocols[2]. Hormonal status may influence response, but specific adjustments have not been systematically studied[3].
How long should you take Vesugen?
Research protocols typically employ 30-60 day treatment cycles with rest periods of equal duration between courses[4]. Some studies have extended treatment to 90 days for chronic conditions, but long-term safety data beyond this timeframe is lacking[2]. The optimal treatment duration likely depends on individual response and specific therapeutic goals[3].
Is a higher dose more effective?
Higher doses do not necessarily provide greater benefits and may cause excessive cellular stimulation[3]. Research indicates an optimal therapeutic range of 20-60 mcg daily, with diminishing returns and potential adverse effects at higher doses[2]. Individual optimization within this range based on biomarker response appears more effective than simply increasing dose[5].
Can Vesugen be taken with other peptides?
Some research has examined combination therapy with other bioregulatory peptides like Pinealon, suggesting potential synergistic effects[4]. However, specific dosing adjustments for combination therapy have not been systematically studied[2]. Medical supervision becomes even more critical when combining multiple peptides due to unknown interaction effects[3].
How should Vesugen be stored?
Lyophilized Vesugen must be stored at 2-8°C (36-46°F) and maintains stability for 24-36 months under proper conditions[2]. Reconstituted solutions remain stable for 14-21 days when refrigerated, but lose potency rapidly at room temperature[3]. Never freeze reconstituted solutions, as this causes protein aggregation and complete loss of biological activity[2].
References
- U.S. Food and Drug Administration. "Regulatory Status of Peptide Bioregulators." FDA.gov. Accessed 2026.
- Khavinson VK, et al. "Peptides tissue-specifically stimulate cell differentiation during their aging." Bull Exp Biol Med. 2012;153(2):259-262. PMID: 22808515
- Khavinson VK, et al. "Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging." Adv Gerontol. 2014;27(2):234-240. PMID: 25051766
- Khavinson VK, et al. "Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission." Adv Gerontol. 2015;28(3):462-465. PMID: 26390612
- Khavinson VK, et al. "Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro." Bull Exp Biol Med. 2016;161(2):175-180. PMID: 27259496
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.
